Guardant Health (NASDAQ:GH) Director Sells $117,256.40 in Stock

Key Points

• Director Selling: Guardant Health's Director, Medina Manuel Hidalgo, sold 2,165 shares for $117,256.40, representing a 71.78% decrease in their holdings.
• Financial Performance: The company reported a 31% year-over-year increase in revenue for the last quarter, totaling $232.09 million, exceeding analyst expectations.
• Analyst Ratings: Guardant Health has received a consensus rating of "Buy" from analysts, with price targets ranging from $58.24 to $70.00.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Medina Manuel Hidalgo sold 2,165 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the sale, the director directly owned 851 shares of the company's stock, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Guardant Health Stock Performance

Shares of GH stock traded down $0.11 during trading hours on Monday, hitting $54.79. The company had a trading volume of 2,412,572 shares, compared to its average volume of 2,215,055. The company's fifty day moving average is $53.91 and its 200 day moving average is $47.81. Guardant Health, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $68.00.

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.08. The business had revenue of $232.09 million for the quarter, compared to analyst estimates of $211.19 million. Guardant Health's quarterly revenue was up 31.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Institutional Trading of Guardant Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Driehaus Capital Management LLC bought a new position in Guardant Health during the 1st quarter valued at $82,349,000. ARK Investment Management LLC increased its holdings in shares of Guardant Health by 100.4% in the 2nd quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company's stock worth $146,935,000 after acquiring an additional 1,414,381 shares during the period. Invesco Ltd. raised its holdings in shares of Guardant Health by 100.9% during the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company's stock valued at $119,053,000 after buying an additional 1,403,670 shares during the last quarter. Norges Bank acquired a new position in shares of Guardant Health during the second quarter valued at $64,136,000. Finally, Two Sigma Advisers LP increased its stake in Guardant Health by 96.7% during the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock valued at $70,742,000 after buying an additional 1,138,300 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GH has been the topic of a number of analyst reports. Evercore ISI upgraded shares of Guardant Health to a "strong-buy" rating in a report on Monday, July 14th. BTIG Research raised their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday, September 4th. Mizuho boosted their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Friday, June 13th. Scotiabank boosted their price target on shares of Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a research note on Thursday, July 31st. Finally, Raymond James Financial upped their target price on shares of Guardant Health from $59.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. According to MarketBeat, Guardant Health currently has an average rating of "Buy" and a consensus target price of $58.24.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.